Cadent Therapeutics to Present at Upcoming Investor Conferences
November 14, 2019CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the following upcoming investor conferences:
Stifel 2019 Healthcare Conference
Date: Wednesday, November 20, 2019
Presentation: 8:35 – 9:05 a.m. ET
Location: Lotte New York Palace
Jefferies London Healthcare Conference
Date: Thursday, November 21, 2019
Presentation: 6:00 – 6:35 p.m. GMT
Location: London, UK
About Cadent Therapeutics
Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive disorders. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor, and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com.
Contacts
Investors:
Maeve Conneighton, [email protected]
212.600.1902
Media:
David Rosen, [email protected]
212.600.1902